Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:KYMR NYSE:QGEN NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$194.30+0.8%$178.20$111.09▼$199.99$11.80B0.41572,249 shs308,107 shsKYMRKymera Therapeutics$44.10+3.5%$44.17$19.44▼$53.27$3.05B2.18660,761 shs508,269 shsQGENQiagen$49.71+1.2%$48.61$37.63▼$51.88$10.92B0.641.36 million shs882,883 shsRDYDr. Reddy's Laboratories$14.52+0.7%$14.60$12.26▼$16.77$12.04B0.291.34 million shs1.03 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.78%-2.03%+14.20%+19.94%+41.82%KYMRKymera Therapeutics+3.55%+3.45%-5.02%+49.54%-9.17%QGENQiagen+1.18%+0.72%-1.38%+18.17%+8.68%RDYDr. Reddy's Laboratories+0.81%+2.07%-0.89%+0.94%-13.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.2954 of 5 stars4.51.00.00.03.41.70.6KYMRKymera Therapeutics3.0894 of 5 stars4.61.00.00.02.62.50.0QGENQiagen3.8319 of 5 stars1.12.01.74.53.51.71.9RDYDr. Reddy's Laboratories3.096 of 5 stars2.44.01.70.03.30.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$243.3625.25% UpsideKYMRKymera Therapeutics 3.10Buy$59.1134.04% UpsideQGENQiagen 2.27Hold$49.69-0.06% DownsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9516.78% UpsideCurrent Analyst Ratings BreakdownLatest KYMR, ASND, RDY, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$254.00 ➝ $260.008/15/2025RDYDr. Reddy's LaboratoriesZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/8/2025ASNDAscendis Pharma A/SCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025ASNDAscendis Pharma A/SWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$289.00 ➝ $295.008/8/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$243.00 ➝ $290.008/8/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$210.00 ➝ $230.008/8/2025ASNDAscendis Pharma A/SUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$306.00 ➝ $307.008/8/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$212.00 ➝ $220.008/8/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $203.008/8/2025ASNDAscendis Pharma A/SStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$212.00 ➝ $254.008/7/2025QGENQiagenCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M30.22N/AN/A($3.48) per share-55.83KYMRKymera Therapeutics$44.71M70.52N/AN/A$13.59 per share3.25QGENQiagen$1.98B5.59$3.24 per share15.33$15.77 per share3.15RDYDr. Reddy's Laboratories$3.81B3.18$1.04 per share13.97$4.94 per share2.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A809.58N/A-54.94%N/A-24.31%N/AKYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)QGENQiagen$83.59M$1.6929.3720.212.5818.30%14.77%8.87%11/5/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6621.9917.705.8116.99%17.25%11.63%11/4/2025 (Estimated)Latest KYMR, ASND, RDY, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AQGENQiagen$0.250.50%N/A14.79%N/ARDYDr. Reddy's Laboratories$0.070.48%N/A10.61%N/ALatest KYMR, ASND, RDY, and QGEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/1/2025QGENQiagen$0.250.52%7/2/20257/3/20257/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69KYMRKymera TherapeuticsN/A8.328.32QGENQiagen0.251.611.35RDYDr. Reddy's Laboratories0.011.891.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AKYMRKymera TherapeuticsN/AQGENQiagen70.00%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%KYMRKymera Therapeutics16.01%QGENQiagen9.00%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.21 million36.73 millionOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableKYMR, ASND, RDY, and QGEN HeadlinesRecent News About These CompaniesGroupama Asset Managment Buys New Position in Dr. Reddy's Laboratories Ltd $RDYAugust 23 at 5:58 AM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Trims Position in Dr. Reddy's Laboratories Ltd $RDYAugust 22 at 3:37 AM | marketbeat.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Given Consensus Recommendation of "Moderate Buy" by AnalystsAugust 21 at 8:26 AM | marketbeat.comCorient IA LLC Acquires New Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 20 at 6:33 AM | marketbeat.comVestmark Advisory Solutions Inc. Increases Stock Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 20 at 5:10 AM | marketbeat.comExtrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.August 18, 2025 | globenewswire.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Bought by National Bank of Canada FIAugust 18, 2025 | marketbeat.comZacks Research Has Optimistic Outlook of RDY Q1 EarningsAugust 16, 2025 | marketbeat.comZacks Research Has Pessimistic Outlook of RDY Q2 EarningsAugust 15, 2025 | marketbeat.com21,345 Shares in Dr. Reddy's Laboratories Ltd (NYSE:RDY) Purchased by LGT Group FoundationAugust 15, 2025 | marketbeat.comTriglav Skladi D.O.O. Takes $857,000 Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 14, 2025 | marketbeat.comAIA Group Ltd Sells 101,293 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 14, 2025 | marketbeat.comQ2 EPS Forecast for Dr. Reddy's Laboratories Cut by AnalystAugust 14, 2025 | americanbankingnews.comDr. Reddy’s Laboratories to Engage in Virtual Investor Conference on August 21, 2025August 13, 2025 | msn.comNatixis Advisors LLC Trims Stock Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 13, 2025 | marketbeat.comDr. Reddy’s Subsidiary Imperial Dissolved Following NCLT ApprovalAugust 12, 2025 | theglobeandmail.comXY Capital Ltd Sells 47,520 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 9, 2025 | marketbeat.comUS Bancorp DE Has $2.15 Million Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 9, 2025 | marketbeat.comPinpoint Asset Management Ltd Reduces Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 8, 2025 | marketbeat.comEnvestnet Asset Management Inc. Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)August 7, 2025 | marketbeat.comDr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New RevenuesAugust 4, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYMR, ASND, RDY, and QGEN Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$194.30 +1.50 (+0.78%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$194.17 -0.13 (-0.07%) As of 08/22/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Kymera Therapeutics NASDAQ:KYMR$44.10 +1.51 (+3.55%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$43.54 -0.56 (-1.26%) As of 08/22/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Qiagen NYSE:QGEN$49.71 +0.58 (+1.19%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$49.74 +0.02 (+0.04%) As of 08/22/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Dr. Reddy's Laboratories NYSE:RDY$14.52 +0.10 (+0.66%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$14.60 +0.09 (+0.62%) As of 08/22/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access